CURRICULUM VITAE

Sanford Chen, M.D.

Fellow, American Academy of Ophthalmology
Fellow, American College of Surgeons
CA Medical License #G77086

Mailing/Contact Address:
Orange County Retina Medical Group
1200 North Tustin Avenue, Suite 140
Santa Ana, California 92705
714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Partner/Clinical Trial Investigator
Since 9/1/1993

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

EDUCATION AND TRAINING

Vitreo-Retinal Fellowships
Clinical Fellow in Vitreoretinal Diseases and Surgery
Harvard Medical School, Massachusetts Eye and Ear Infirmary
Eye Research Institute of The Retina Foundation, Boston, Massachusetts, 1991-1993

Retina Research Fellow
Harvard Medical School
Schepens Eye Research Institute, Boston, Massachusetts, 1991-1993

Residency in Ophthalmology
University of Pennsylvania School of Medicine
Scheie Eye Institute, Philadelphia, Pennsylvania, 1988-1991

Internship in Medicine
Yale University School of Medicine
Yale-New Haven Hospital, New Haven, Connecticut, 1987-1988

Accelerated Pre-Medical/Medical Program
Bachelor of Science, Biomedical Sciences/Medical Doctorate
University of Michigan, Ann Arbor, Michigan, 1981-1987

Secondary Education
The Perse School for Boys, Cambridge, England, 1978-1979
Wylie E. Groves High School, Birmingham, Michigan, 1979-1981

BOARD CERTIFICATION

National Board of Medical Examiners
American Board of Ophthalmology

LICENSURE

California, Issued 1993

HONORS AND ACHIEVEMENTS

Top Doctors, US News and World Report

Castle Connolly Top Doctor

Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2018, 2017, 2016, 2015, 2014, 2013, 2012, 2010, 2009, 2008, 2006, 2005

Patients' Choice Physician Award, MDx Medical 2012, 2009

Volunteer Faculty Recognition Certificate for16 Years of Service
Department of Ophthalmology, School of Medicine
University of California, Irvine, CA, April 2010

America's Top Ophthalmologists, Consumers' Research Council of America, 6th Edition, 2009

Super Doctors of Los Angeles, Key Professional Media, November 2008

Life Member, National Registry of Who's Who, 2001

Honored Member, Strathmore's Who's Who in America, 1999-2000

Outstanding Young Men of America, 1998

Golden Key National Honor Society

Frank Robbins Scholarship

University of Michigan Alumni Award Scholarship

State of Michigan Competitive Scholarship

Magna Cum Laude

Phi Beta Kappa

Who's Who in American Schools

Winner of American Association of Teachers of French National Language Contest

Certificate of High Scholarship

National Honor Society

MENSA

PROFESSIONAL BACKGROUND

2012-Present	Consulting Physician, Genentech, Inc., San Francisco, California
2012-Present	Consulting Physician, Regeneron Pharmaceuticals, Tarrytown, New York
2010-Present	Associate Clinical Professor in Ophthalmology, University of California, Irvine School of Medicine
2008-Present	Consulting Physician, Alimera Sciences, Alpharetta, Georgia
2005-Present	Reviewer, British Journal of Ophthalmology
2005-Present	Retinal Advisory Council II, Alcon Surgical, Irvine, California
2005-2009	National Hockey League Team Retina Physician/Surgeon, Anaheim Ducks, Anaheim, California
May 2004	Honorary Professor, Liao Cheng People's University & Hospital, Liao Cheng, China
2001-Present	Consulting Physician, Allergan, Irvine, California
2001-Present	Reviewer: Archives of Ophthalmology
2000-Present	Novartis Ophthalmics Advisory Board
2000-Present	Reviewer, Ophthalmology Journal of the American Academy of Ophthalmology, Elsevier Publications
2000-Present	Physician's Advisory Board, National Republican Congressional Committee, Washington, D.C.
2000-Present	Consulting Physician, Leerink, Swann, & Company / MEDACorp, Boston, Massachusetts
1995-2006	Consulting Physician, Veterans Administration Hospital, Long Beach, California
1994-2010	Assistant Clinical Professor in Ophthalmology, University of California, Irvine School of Medicine
1991-1993	Research Associate, Eye Research Institute of the Retina Foundation, Harvard Medical School, Boston, Massachusetts
1988-1991	Instructor in Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Speakers Bureau	**Advisory Boards**	**Past Speakers Bureau/ Advisory Boards**
Alcon Laboratories	Alcon Laboratories	Eyetech Inc.
Allergan	Allergan	Inspire Pharmaceuticals
Genentech	Genentech	Novartis Ophthalmics
Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	Pfizer Ophthalmics
		Thrombogenics

PROFESSIONAL SOCIETY MEMBERSHIPS

1988 – Present	American Academy of Ophthalmology, Fellow
1989 – Present	Chinese American Ophthalmological Society
1989 – Present	Association for Research in Vision and Ophthalmology
1993 – Present	California Medical Association
1993 – Present	Orange County Medical Association
1993 – Present	California Association of Eye Physicians and Surgeons
1993 – Present	Orange County Society of Ophthalmology Executive Committee, Program Chairman, 1998-1999 Secretary/Treasurer, 1999-2001 Vice President, 2002-2003 President, 2004-2005
1993 – Present	Schepens International Society
1994 – Present	American College of Surgeons
1995 – Present	American Society of Retina Specialists (The Vitreous Society)
1996 – Present	Western Retina Study Club
2004 – Present	Club Vit

HOSPITAL/SURGERY CENTER AFFILIATIONS

1993 – 2015	Western Medical Center, Santa Ana, California
1994 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
1994 – Present	St. Joseph Hospital, Orange, California
1994 – Present	Children's Hospital of Orange County, Orange, California
1994 – Present	Pacific Hills Surgery Center, Laguna Hills, California
1997 – Present	Anaheim Regional Medical Center, Anaheim, California
2002 – Present	Children's Hospital at Mission, Mission Viejo, California
2010 – Present	Barranca Surgery Center, Irvine, California
2015 – Present	Orange County Global Medical Center (formerly Western Medical Center), Santa Ana, California

PROFESSIONAL PRESENTATIONS

01. *The Acute Effect of Topical Epinephrine on Macular Blood Flow in Humans*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; April 1990

02. *Does Topical Timolol Affect Human Macular Capillary Blood Flow?*
University of Pennsylvania Alumni Meeting, Philadelphia, Pennsylvania; April 1991

03. *Advances in Genetic Eye Diseases: Genetics of Retinoblastoma*
Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; January 1992

04. *Acute Myelogenous Leukemia Presenting as Central Serous Retinopathy*
Schepens Alumni Meeting, Boston, Massachusetts; June 1992

05. *The Mechanism of Optic Nerve and Posterior Pole Injury after Blunt Ocular Trauma*
American Academy of Ophthalmology, Dallas, Texas; November 1992

06. *The Acute Effect of Topical Timolol on Human Macular Capillary Blood Flow*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; May 1993

07. *Current Treatment of Endophthalmitis.*
Advances in Pneumatic Retinopexy.
Surgical Management of Dislocated Lens.
Humanitarian Trip, Yerevan, Armenia; September 1994

08. *Techniques and Complications of Pneumatic Retinopexy*
American College of Surgeons: Indian Wells, California; January 1995

09. *New Advances in Diabetic Retinopathy*
Humanitarian Trip, Yerevan, Armenia; September 1995

10. *Age-Related Macular Degeneration & Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 1997

11. *The Use of Silicone Oil in Pseudophakic Patients*
American Society of Cataract and Refractive Surgeons, Boston, Massachusetts; April 1997

12. *Age-Related Macular Degeneration and Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 1998

13. *Age-Related Macular Degeneration and Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology; January 1999

14. *Unifocal Helioid Choroidopathy*
Western Retina Study Club, Newport Beach, California; March 1999

15. *Nursing Implications for Retinopathy of Prematurity*
St. Joseph Hospital, Orange, California; May 1999

16. *Retinopathy of Prematurity Screening*
Children's Hospital of Orange County, Orange, California; May 1999

17. *Diabetes and the Eye - The Importance of the Seven Fields in Diabetic Retinopathy*
Ophthalmic Photographers' Society, Los Angeles, California; June 1999

18. *Retinopathy of Prematurity Screening*
Martin Luther Hospital, Anaheim, California; July 1999

19. *Retinopathy of Prematurity*
Children's Hospital of Orange County, Orange, California; November 1999

20. *Age-related Macular Degeneration & Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 2000

21. *Innovations in Treatment of Macular Degeneration*
EENT Department Presentation, St. Joseph Hospital, Orange, California July 2000

22. *An Introduction to Photodynamic Therapy*
Ophthalmic Photographers' Society, San Diego, California; August 2000

23. *Latest Developments in Retinopathy of Prematurity*
California Children's Services, Orange County, Santa Ana, California; May 2001

24. *Multiple Cystic Granulomas as a Complication of Silicone Oil Use in Vitreoretinal Surgery*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; May 2001

25. *Update and Review of Visudyne Photodynamic Therapy*
The Western Association for Vitreoretinal Education, Maui, Hawaii; July 2001

26. *Unique Cases of Visudyne Therapy*
National Optometry Advisory Board, Key West, Florida; November 2001

27. *Introduction to Photodynamic Therapy*
Ophthalmic Photographers' Society 32nd Annual Educational Program, New Orleans, Louisiana; November 2001

28. *Managing Patients' Expectations for Verteporfin Therapy*
Royal Hawaiian Eye Meeting, Waikoloa, Hawaii; January 2002

29. *Results of Clinical Trials and Adverse Events*
South America Visudyne Launch "Introduction to Photodynamic Therapy", Lima, Peru; April 2002

30. Council on Optometric Practitioner Education Educators' Meeting: Carlsbad, California
Treatment of AMD with Photodynamic Therapy
April 2002

31. *Clinical Decisions in Managing AMD*
National Optometry Advisory Board, Colorado Springs, Colorado; June 2002

32. *Radial Optic Neurotomy for CRVO*
25g Transconjunctival Vitrectomy
XXXth Congreso Nacional de Oftalmologia, Cartegena, Colombia; September 2002

33. *New Treatment Strategies for AMD*
American Academy of Optometry, San Diego, California; December 2002

34. *Update of New Treatment Options in AMD*
Optometry Educator's Meeting, Scottsdale, Arizona; March 2003

35. *Interpreting Data from Open Label Phase I/II AMD Trials*
American Society of Retina Specialists Annual Meeting, New York, New York; September 2003

36. *Retinopathy of Prematurity*
Resident Conference Lecture Children's Hospital of Orange County; September 2003

37. *Treatment Trends in Macular Disease*
Ophthalmic Photographers' Society 34th Annual Educational Program, Anaheim, California; November 2003

38. *Retinopathy of Prematurity*
Children's Hospital of Orange County, Orange, California; May 2004

39. *New Advances in Surgical Retina*
Goodwill Medical Delegation. Jinan, Liao Cheng, Cheng Du, Shanghai, Peoples' Republic of China; May 2004

40. *The Great Debates: Controversies in Retinal Disease 2005*
Invited Speaker. Medical Education Seminar, University of California, Irvine, Beckman Laser Center; March 2005

41. *Retinopathy of Prematurity*
Resident Lecture. Children's Hospital of Orange County, Orange, California; March 2006

42. *Management of AMD: Looking to the Future*
Rio Hondo Optometric Society, La Mirada, California; June 2007

43. *Short Term Outcomes of Multi-center 23g Vitrectomy*
Club Vit Meeting, Bachelor Gulch, Colorado; July 2007

44. *Evolution Of AMD Management*
Invited Speaker. QLT Meeting, Honolulu, Hawaii; October 2007

45. *New Clinical Trials for Age-Related Macular Degeneration*
Rio Hondo Optometric Society, La Mirada, California; November 2007

46. *Advances in Treatment for Exudative Age-Related Macular Degeneration*
Novartis Speaking Engagement, Park City, Utah; April 2008

47. *Strategies for Managing Patients with Neovascular AMD – A Case Study Series*
Novartis Speaking Engagement, Los Angeles, California; September 2008

48. *Alimera Sciences FAME Study. 36-Month Results of Iluvien: Single Insert Outcomes*
Club Vit Meeting, Santa Monica, California; 2011

49. *Voclosporin: Overview and Clinical Development*
Lux Protocol LX211-11, Lux Biosciences, Costa Mesa, California; September 2011

50. *Minimizing Intraoperative Hypotony during Vitrectomy*
American Society of Retina Specialists, Las Vegas, Nevada; August 2012

51. *Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis*
EyeGate Protocol EGP-437-004, EyeGate Pharma, Anaheim, California; October 3, 2012

52. *Developments in the Treatment of Wet AMD*
Regeneron Educational Program, Retina Associates of Orange County, Laguna Hills, California; March 18, 2013

53. *Developments in the Treatment of Wet AMD*
Regeneron Educational Program, Retina Institute, Orange, California; April 4, 2013

54. *Macular OCT: Mastering the Basics*
Instructional Course. American Academy of Ophthalmology, New Orleans, Louisiana; November 17, 2013

55. *Current Treatments for Wet AMD*
Retina Care Symposium, Costa Mesa, California; December 5, 2013

56. *Ozurdex for the Treatment of Diabetic Macular Edema in Vitrectomized Patients*
Retina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20, 2014

57. *Gevokizumab for Patients with Uveitis: Background of Interleukins*
Retina Care for Rheumatologists, Santa Ana, California; June 4, 2014

58. *OCT and Macular Disease*
NVISION Annual Summer Symposium Program, Anaheim, California; June 22, 2014

59. *Use of Ozurdex Implant in Diabetic Macular Edema*
Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine, California; September 10, 2014

60. *Retina Case Studies*
Implantable Miniature Telescope and Interesting Retina Cases, Costa Mesa, California; October 1, 2014

61. *Phase I Results*
Allergan CEDAR Study. Beyond Anti-VEGF: New Drug Molecule for Wet AMD, Costa Mesa, California; September 30, 2015

62. *Potential New Treatment for Dry Age-related Macular Degeneration: Mechanism of Action*
Roche/Genentech CHROMA Study., Newport Beach, California; October 29, 2015

63. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

64. *Beyond Anti-VEGF: New Drug Molecule for Wet AMD*
Allergan Protocol #150998-005 "CEDAR" Study. Costa Mesa, California; July 21, 2016

65. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

66. *Surgically Implanted Ranibizumab Reservoir fro Wet AMD*
Genentech/Roche Protocol #GX28228 "LADDER" Study. Anaheim, California; August 24, 2016

67. *Novel Technique: Suprachroidal Drug Treatment for Uveitic Macular Edema*
Clearside Biomedical Protocol #CLS1001-301 "PEACHTREE" Study. Anaheim, California; June 1, 2016

68. *New Treatment Paradigm? Iontophoretic Dexamethasone for Anterior Uveitis*
Eyegate Protocol #EGP-437-006 Study. Newport Beach, California; October 6, 2016

69. *A Multidisciplinary Approach to Management of Diabetic Eye Disease*
Allergan Clinical Exchange Program. Costa Mesa, California; November 17, 2016

70. *New Treatment Paradigm Series: Stem Cell Patch for Severe Vision Loss*
Regenerative Patch Technologies Protocol #RPT-14-01. Newport Beach, California; June 1, 2017

71. *New Treatment Paradigm Series: Suprachoroidal Therapy for Retinal Vein Occlusion*
Clearside Biomedical Protocol #CLS1003-301,. Newport Beach, California; August 30, 2017

72. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Uveitis*
Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; March 21, 2018

73. *New Treatment Paradigm Series: Novel Biologic Therapy for Wet AMD*
Iconic Therapeutics Protocol #IT-004, Newport Beach, California; August 29, 2018

74. *New Treatment Paradigm Series: Novel Therapy for Non-Infectious Anterior Uveitis*
Aldeyra Therapeutics Protocol #ADX-102-UV-005, Newport Beach, California; February 12, 2019

74. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Genentech Protocol #GR40548 "ARCHWAY", Newport Beach, California; February 26, 2019

75. *New Treatment Paradigm Series: Surgically Implanted Ranibizumab Reservoir for Wet AMD*
Genentech Protocol #GR40548 "ARCHWAY", Newport Coast, California; February 28, 2019

76. *New Treatment Paradigm Series: New Molecule for the Treatment of DME*
Genentech Protocol #GR40349 "YOSEMITE", Irvine, California; March 7, 2019

PUBLIC PRESENTATIONS

01. *Diabetic Retinopath*y
Project Health, Western Medical Center, Santa Ana, California; October 1995

02. *Diabetic Retinopathy*
Project Health, Saddleback Medical Center, Laguna Hills, California; April 1996

03. *Complications of Diabetes*
Diabetes Education Series, Invited Speaker, Placentia Linda Hospital, Placentia, California; May 1996

04. *Diabetes and Eye Disease*
Diabetic Discussion Group, Invited Speaker, Costa Mesa Senior Center, Costa Mesa, California; March 1998

05. *Living Well with Diabetes*
Invited Speaker. Diabetes Education Lecture, Placentia Linda Hospital, Placentia, California; September 1998

06. *Photodynamic Therapy for Macular Degeneration*
Invited Speaker. Anaheim Community Center, Anaheim, California; October 2002

07. *Macular Degeneration*
Community Education Lecture, Mission Regional Medical Center, Mission Viejo, California; May 2003

08 *Optic Nerve Swelling*
"The Doctors" CBS Television Production, Broadcast Airing February 9, 2009

09. *Optic Nerve Abnormalities*
"The Doctors" CBS Television Production, Broadcast Airing March 11, 2009

10. *Macular Degeneration*
"The Doctors" CBS Television Production, Broadcast Airing: March 23, 2009

11. *Macular Degeneration and Diabetes Seminar*
Invited Speaker. Low Vision Council, Southern California College of Optometry, Fullerton, California; June 2011

12. *Retina: The Eyes are the Window to Your Soul*
Hallmark Channel: "Home & Family", Television Broadcast Airing: May 23, 2014

CLINICAL RESEARCH

01. Wyeth-Ayerst Pharmaceutical; 1993
Sub-Investigator. *Safety and efficacy of Tolrestat in the treatment of diabetic retinopathy*

02. CIBA/QLT PhotoTherapeutics, Protocol BPD-OCR-005 (VAM); 1999
Principal Investigator. *An open-label multicenter safety study of the treatment of predominantly classic subfoveal CNV secondary AMD using PDT with verteporfin for injection*

03. Eyetech Pharmaceuticals, Protocol EOP 1004, Phase II/III; 2001-2005
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD*

04. Novartis Ophthalmics, Protocol CBPD952A2201 (ADD-V), Phase II; 2002
Principal Investigator. *ADjunctive Diclofenac therapy and Visudyne PDT (ADD-V): A three-month randomized, placebo-controlled, double-masked, multicenter study of the effect of adjunctive diclofenac therapy and Visudyne PDT in patients with predominantly classic subfoveal CNV secondary to AMD*

05. Alcon Research, Ltd., Protocol C-01-99, Phase III; 2002-2005
Sub-Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD*

06. OxiGENE, Inc., Protocol MMD-213, Phase III; 2004-2006
Principal Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia*

07. Diabetic Retinopathy Clinical Research Network/National Eye Institute, Protocol B; 2004-2009
Principal Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME*

08. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III; 2004-2009
Principal Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtascleral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD*

09. National Eye Institute, SCORE; 2004-2009
Principal Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO*

10. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV, Collaborative Study; 2005-2006
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction*

11. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III; 2005-2007
Sub-Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 months in patients with exudative AMD*

12. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV; 2005-2007
Principal Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD*

13. Novartis, Protocol CBPD952E2202 (VERITAS), Phase IIIB; 2005-2007
Sub-Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptnanib (Macugen) in patients with subfoveal CNV secondary to AMD*

14. Alcon, Accurus 23G PPV Field Study; 2006-2007
Principal Investigator. *Short-term outcomes of 100 consecutive cases of Alcon 23 gauge surgery for posterior segment diseases (a retrospective, consecutive multicenter, multisurgeon, case series of the short term safety and efficacy of 23 gauge micro-incision pars plana vitrectomy [PPV] surgery using the Alcon 23gauge micro-incision system for a variety of retinal conditions on previously non-vitrectomized eyes)*

15. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV; 2006-2008
Sub-Investigator. *An open label, multicenter trial of maintenance intravitreous injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement*

16. QLT Inc./RVT 002 (Registry II) (QUEST); 2006-2008
Principal Investigator. *Registry for QLT using Visudyne in evaluation of sequential and triple therapies*

17. Novartis, Protocol CBPD952A2308 (DENALI), Phase IIIB; 2006-2010
Sub-Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizimub (Lucentis) versus ranibizumub (Lucentis) monotherapy in patients with subfoveal CNV secondary to AMD*

18. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III; 2006-2011
Principal Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®)*

19. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III; 2006-2011
Principal Investigator. *CLinical Evaluation of Anti-angiogenesis in the Retina - Intravitreal Trial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD*

20. Opko, Protocol ACU-301 (COBALT), Phase III; 2007-2009
Principal Investigator. *COmbining Bevasirinib and Lucentis Therapy (COBALT): A randomized, double-masked, parallel-assignment study of intravitreal bevasirinib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD*

21. Allergan, Protocol 206207-012, Phase III; 2007-2010
Principal Investigator. *A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700ug dexamethasone posterior-segment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME*

22. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III; 2007-2010
Principal Investigator. *A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR*

23. Merck & Co., Protocol 007-01, Collaborative Study; 2008-2009
Ophthalmology Investigator. *A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB*

24. Allergan, Protocol 206207-019-00, Phase II; 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD*

25. Ophthotech Corp., Protocol OPH3000, Phase I; 2008-2010
Principal Investigator. *An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreous injections of volociximab ($\alpha5\beta1$ integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD*

26. Regeneron, Protocol VGFT-OD-0706 (DA VINCI); Phase III, 2008-2011
Principal Investigator. *A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME*

27. NEI/Tufts Medical Center, The Family Study of Macular Degeneration; 2009-2010
The goal is to evaluate genetic and non-genetic risk factors for AMD

28. Allergan, Protocol 206207-018-00, Phase II; 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME*

29. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study; 2009-2011
Sub-Investigator. *A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy*

30. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study; 2010-2011
Sub-Investigator. *A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain*

31. GlaxoSmithKline, Protocol MD 7110852, Phase IIB; 2009-2012
Sub-Investigator. *A dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD*

32. Genentech, Protocol FVF4579g (HARBOR), Phase III; 2009-2012
Principal Investigator. *A double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD*

33. Lux Biosciences, Inc., Protocol LX211-11, Phase III; 2011-2013
Principal Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis*

34. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2011-2015
Principal Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation of Isonep™ (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to age-related macular degeneration*

35. Alimera Sciences, Protocol C-01-11-008 (FAME), Extension Study; 2011-2013
Principal Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME*

36. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III; 2012-2013
Principal Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*

37. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II; 2012-2013
Principal Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*

38. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD™ -A), Phase III; 2012-2015
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*

39. Pfizer, Protocol B1181003-1050 (DREAM), Phase II; 2012-2013
Principal Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*

40. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III; 2012-2015
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*

41. Regeneron, Protocol VGFTe-AMD-1124 (RE-VIEW), Phase IV; 2012-2015
Principal Investigator. *Rigorous evaluation of vision and safety with intravitreal afliberecept injection dosed every 8 weeks over 2 years in neovascular AMD*

42. Merck, Protocol MK8931-017 (SCH 900931, P07738) (EPOCH), Phase 2/3, Collaborative Study; 2012-2018
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate alzheimer's disease*

43. Ophthotech, Protocol OPH1003 (ECLIPSE), Phase III; 2013-2017
Principal Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista ™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*

44. Allergan, Protocol GMA-OZU-13-598 (ECHO), Retrospective Registry; 2013-2014
Principal Investigator. *A retrospective data collection study in patients receiving anti-VEGF injections for retinal vein occlusion or diabetic macular edema*

45. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II; 2014-2015
Sub-Investigator. *A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic macular edema*

46. Xoma, Protocol #X052132 (EYEGUARD™ -E), Phase III; 2014-2016
Sub-Investigator. *An open-label, non-randomized, single-arm, roll-over study to continue dosing of gevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfully completed either the X052130 or the X052131 study*

47. Merck, Protocol #MK8931-019 (APECS), Phase III, Collaborative Study; 2014-2018
Ophthalmology Investigator. *A phase III, randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH900931) in subjects with amnestic mild cognitive impairment due to alzheimer's disease (prodromal AD)*

48. National Eye Institute, SCORE2, Phase III; 2014-2016
Principal Investigator. *A multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal afliberecept every 4 weeks*

49. Allergan, Protocol 150998-004 (PALM), Phase II; 2014-2015
Sub-Investigator. *Evaluation of Abicipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema*

50. Thrombogenics, Protocol TG-MV-018 (ORBIT), Prospective Registry, Phase IV; 2014-2016
Principal Investigator. *Ocriplasmin Research to Better Inform Treatment*

51. Thrombogenics, Protocol TG-MV-022 (OZONE), Retrospective Registry, Phase IV; 2014-2015
Principal Investigator. *Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study*

52. Allergan, Protocol GMA-US-EYE-0272 (REINFORCE), Prospective Registry, Phase IV; 2014-2016
Principal Investigator. *The Ozurdex Diabetic Macular Edema Patient Registry*

53. Hoffmann-La Roche, Protocol GX29176 (CHROMA), Phase III; 2014-2018
Principal Investigator. *A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration*

54. Xoma, Protocol X052133 (EYEGUARD™ -US), Phase III; 2015-2015
Sub-Investigator. *A randomized-withdrawal, double-masked, placebo-controlled study of the efficacy and safety of gevokizumab in treating subjects with Behçet's disease uveitis*

55. Allegro Ophthalmics, Protocol DME-202B (DEL MAR), Phase II; 2015-2015
Principal Investigator. *A phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate® (ALG-1001) as compared to Avastin® and focal laser photocoagulation in the treatment of diabetic macular edema*

56. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-2016
Primary Investigator. *A phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1™ in patients with choroidal neovascularization secondary to age-related macular degeneration*

57. Bayer, Protocol BAY 73-4506/15984 (DREAM), Phase IIa/IIB; 2015-2015
Sub-Investigator. *A combined phase IIa/IIb study of the efficacy, safety and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration*

58. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present
Principal Investigator. *A multicenter, randomized, double-masked, parallel-group, active-controlled study evaluating the safety and efficacy of abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration*

59. Ophthotech, Protocol OPH1004, Phase III; 2015-2017
Principal Investigator. *A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (anit PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

60. Ophthotech, Protocol OPH1005 Phase III; 2015-2017
Sub-Investigator. *A 24 month, phase 2a, open label, safety study of Fovista (anti-PDGF-BB pegylated aptamer) regimen administered in combination with anti-VEGF therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy*

61. Ophthotech, Protocol OPH1006 Phase III; 2015-2017
Sub-Investigator. *Effect of anti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*

62. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-2017
Principal Investigator. *A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration*

63. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-2016
Sub-Investigator. *A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema*

64. Alcon, Protocol RTH258-C001 (HAWK), Phase III; 2015-2018
Principal Investigator. *A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus afliberecept in subjects with neovascular age-related macular degeneration*

65. Clearside Biomedical Protocol CLS1001-301 (PEACHTREE), Phase III; 2015-2018
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*

66. Genentech/Roche, Protocol GX28228 (LADDER), Phase II; 2016-Present
Principal Investigator. *A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular AMD*

67. Alimera, Iluvien Prospective Registry, Phase IV; 2016-2018
Principal Investigator. *Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg patient case study data collection registry*

68. Alimera, Protocol M-01-15-004 (PALADIN), Phase IV; 2016-Present
Sub-Investigator. *A phase IV safety study of IOP signals in patients treated with Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg*

69. Arctic Diagnostics, Protocol AMD SCI-GEN, Observational Registry, 2016-2018
Site Investigator. *AMD study of the clinical impact of genetics*

70. Eyegate EGP-437-006, Phase III; 2016-2018
Principal Investigator. *A prospective, multicenter, randomized, double-masked, positive-controlled, phase 3 clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*

71. ThromboGenics, Protocol TG-MV-015 (CIRCLE), Phase II; 2016-Present
Sub-Investigator. *A Phase 2, randomized, double-masked, sham-controlled, multi-centre study to evaluate the efficacy and safety of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR)*

72. L. Hoffmann-La Roche, Protocol BP29647 (AVENUE), Phase II; 2016-2018
Principal Investigator. *A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigator the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration*

73. L. Hoffmann-La Roche, Protocol BP30099 (BOULEVARD), Phase II; 2016-2017
Sub-Investigator. *A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with diabetic macular edema*

74. Actelion, Protocol ACT-058B301 (OPTIMUM), Phase III Collaborative Trial; 2016-Present
Sub-Investigator. *Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis*

75. Eli Lilly, Protocol I7X-MC-LLCF (NAVIGATE-AD), Phase II Collaborative Trial; 2016-2018
Ophthalmology Investigator. *Effect of LY3202626 on alzheimer's disease progression as measured by cerebral 18 F-AV-1451 Tau-PET in mild alzheimer's disease dementia*

76. Clearside, Protocol CLS1001-303 (MAGNOLIA), Phase III; 2017-2018
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*

77. Genentech/Roche, Protocol GX30191 (OMASPECT), Phase IIIb; 2017-2018
Principal Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponsored study*

78. Clearside, Protocol CLS1003-301 (SAPPHIRE), Phase III; 2017-2019
Sub-Investigator. *A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal afliberecept in subjects with retinal vein occlusion*

79. Regenerative Patch Technologies, Protocol RPT-14-001, Phase I; 2017-Present
Principal Investigator. *A phase I/IIA safety study of subretinal implantation of CPCB-RPE1 (human embryonic stem cell-derived retinal pigment epithelial (RPE) cells seeded on a polymeric substrate) in subjects with advanced, dry age-related macular degeneration (AMD)*

80. VisionCare, Protocol IMT-TES-2016, Phase IV; 2017-Present
Sub-Investigator. *A prospective, multicenter clinical trial of the implantable miniature telescope in pseudophakic eyes with central vision impairment associated with end-stage macular degeneration. TES Study: Telescope Exchange Study*

81. Regeneron, Protocol VGFTe-OD-1411 (PANORAMA), Phase III; 2017-2018
Principal Investigator. *A phase 3, double-masked , randomized study of the efficacy and safety of intravitreal afliberecept injection in patients with moderately severe to sever non-proliferative diabetic retinopathy*

82. Allergan, Protocol VOLUMA-007 (VOLUMA) Collaborative Study, Phase IV; 2017-2017
Ophthalmology Investigator. *A multicenter, single-blind, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel for correction of temple hollowing*

83. Aldeyra, Protocol ADX-102-UV-005, Phase III; 2017-Present
Sub-Investigator. *A phase 3 randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in subjects with non-infectious anterior uveitis*

84. Ophthotech, Protocol OPH2007, Phase II; 2017-2019
Principal Investigator. *A phase 2A open-label trial to assess the safety of Zimura™ (anti-C5) administered in combination with Lucentis® 0.5mg in treatment naïve subjects with neovascular age-related macular degeneration*

85. Opthea, Protocol OPT-302-1002, Phase III; 2017-Present
Principal Investigator: *A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)*

86. Ophthotech, Protocol OPH2003, Phase II/III; 2017-Present
Principal Investigator: *A phase 2/3 randomized, double-masked, controlledt trial to assess the safety and efficacy of intravitreous administration of Zimura™ (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration*

87. Opthea OPT 302-1003, Phase IB/IIA; 2017-Present
Sub-Investigator: *Phase 1b/2a study of OPT-302 in combination with afliberecept for persistent central-involved diabetic macular edema*

88. Genentech, Protocol GX28228 "LADDER" Sub-Study (OAT), Phase II; 2017-Present
Principal Investigator. Oral antithrombotic therapy substudy in association with study GX28228: *A phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab Port Delivery System for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration*

89. KalVista, Protocol KVD001-2001, Phase II; 2018-Present
Sub-Investigator. *A randomized, sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kalikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment*

90. Iconic, Protocol IT-004 (DECO), Phase II; 2018-Present
Principal Investigator: *A phase 2 randomized, open-label, multicenter study evaluating administration of repeated intravitreal doses of ICON-1 in patients with choroidal neovascularization secondary to age-related macular degeneration*

91. Eli-Lilly, Protocol I5T-MC-AACG (TRAILBLAZER), Phase III, Collaborate Study; 2018-Present
Ophthalmology Investigator. *Assessment of safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic alzheimer's disease*

92. Genentech/Roche, Protocol GR40349 (YOSEMITE), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the simultaneous blockade of antiopoietin-2 and VEGF-A with the bispecific antibody RO6867461 (RG7716) in diabetic retinopathy patients with diabetic macular edema*

93. Genentech/Roche, Protocol GR40549 (PORTAL), Phase III; 2018-Present
Principal Investigator. *A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*

94. Genentech/Roche, Protocol GR40548 (ARCHWAY), Phase III; 2018-Present
Principal Investigator. *A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration*

95. Apellis, Protocol APL2-304 (OAKS), Phase III; 2018-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)*

96. Genentech, Protocol #GR40844 (LUCERNE), Phase III; 2019-Present
Sub-Investigator. *A phase III, multicenter, randomized, double-masked, active comparator, controlled study to evaluate the efficacy and safety of farcimab in patients with neovascular age-related macular degeneration*

ABSTRACTS

01. **Chen S**, Tolentino FI, Wald KJ. Expansile gas in the diagnosis and management of macular holes with retinal detachment. *Retina Society* 1992.

02. Wald KJ, **Chen S**, Buzney SM, Mehta M, Hirose T, Schepens CL. Retinal detachments associated with isolated optic nerve colobomas. *Retina Society* 1992.

03. Stroh EM, Weiter JJ, DeSousa A, **Chen S**, Buzney SM. What's the best way to examine the vitreous? *Retina Society* 1992.

04. **Chen S**, Wald KJ, Weiter JJ. The mechanism of posterior pole injury after blunt ocular trauma. (suppl) *Ophthalmology* 1992;99:9A.

05. Stroh EM, Weiter JJ, DeSousa A, **Chen S**, Buzney SM. Evaluation of the vitreous by clinical and ultrasonographic methods. *Ophthalmology* 1992;99:9A.

06. DeSousa A, Stroh EM, Weiter JJ, **Chen S**, Buzney SM. Comparison of ultrasonographic techniques in the diagnosis of posterior vitreous detachment. *Ophthalmology 1992;*99:9A.

07. Wald K, Hirose T, **Chen S**, Katsumi O, Mehta M, Liberfarb R. Multiple gestation sibships in stage V retinopathy of prematurity. *Ophthalmology 1992;*99:9A.

08. **Chen S**, Maggiano JM. The use of silicone oil in pseudophakic patients. *ASCRS* 1997

09. Ho AC, **Chen S,** Dyer DS, Dugal PU, Gupta S, Kaiser PK, Pollack JS, Regillo CD. The Multi-center 23g microincision vitrectomy study. *Invest Ophthalmol Vis Sci* 2007;48:4.

10. **Chen S**, Abulon DJK. Minimizing intraoperative hypotony during vitrectomy. ASRS 2012

PUBLICATIONS

01. **Chen S**, Robinson F, Riva CE, Petrig BL, Grunwald JE. The acute effects of topical epinephrine on macular blood flow in humans. *Invest Ophthalmol Vis Sci* 1990;31:4.

02. Robinson F, **Chen S**, Petrig BL, Grunwald JE, Riva CE. The acute effect of topical epinephrine on macular blood flow in humans. *Invest Ophthalmol Vis Sci* 1992;33:18.

03. **Chen S**, Stroh EM, Wald K, Jalkh AE. *Xanthomonas maltophilia* endophthalmitis after implantation of a sustained-release ganciclovir implant. *AM J Ophth* 1992;114:6.

04. **Chen S**, Mukai S. Genetics of retinoblastoma. *Int Ophth Clin* 1993;33(1).

05. **Chen S**, Robinson F, Petrig BL, Riva CE. The acute effect of topical timolol on human macular capillary blood flow. *Invest Ophthalmol Vis Sci* 1993;34:4.

06. Stroh EM, **Chen S**, Jalkh AE. Melanocytoma with juxtapapillary nevus: premalignant or benign? *Ann Ophthalmology* 1993;25:11.

07. Brodsky MC, Wald KJ, **Chen S**, Weiter JJ. Protracted post-traumatic optic disc swelling. *Ophthalmology* 1995;102:11.

08. **Chen S**, Nanda M. Ophthalmic surgeries and lasers. *Atlas of Ophthalmic Surgery,* 2nd ed. 1997;Vol. 28:3.

09. Dowell L, **Chen S**. Stereopsis and the ophthalmic photographer: a monocular technique for pairing slides. *J Ophth Photo 1998;*20:87.

10. Tornambe P, **Chen S**, Elliott D, Gallemore R, Jumper J, Nanda S. Advances in the treatment of age-related macular degeneration ophthalmology. *Times* 2005;30:S1.

11. Gupta OP, Ho AC, Kaiser PK, Regillo CD, **Chen S**, Dyer SS, Dugel PU, Gupta S, Pollack JS. Short-term outcomes of 23-gauge pars plana vitrectomy. *Am J Ophthalmol 2008;*146(2):193-197.

12. Campochiaro PA, Brown DM, Pearson A, **Chen S**, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad S, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology* 21Jun2012.

13. You TT, Youn DW, **Chen S**, Alexandrescu B, Casiano ME, Maggiano JM. Unusual ocular injury by an acupuncture needle. *Retinal Cases & Brief Reports*: Spring 2014;Vol.8: Issue 2:116-119.

14. You TT, Huang CX, **Chen S**, Maggiano JM, Rathod RR, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. (Submitted Aug2014, *Retinal Cases & Brief Reports*)

15. Blinder KJ, Dugal PU**, Chen S**, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 2). *Clinical Ophthalmology*: 2017; 11: 393-401.

16. Jumper JM, Dugal PU, **Chen S**, Blinder KJ, Walt JG. Anti-VEGF Treatment of Macular Edema Associated With Retinal Vein Occlusion: Patterns of Use and Effectiveness in Clinical Practice (ECHO Study Report 2). Clin Ophthalmol. 2018; 12: 621–629.